Inhibitor of nuclear factor kappa-B kinase subunit gamma (IKBKG) (IKBKG)

Inhibitor of nuclear factor kappa-B kinase subunit gamma (IKBKG), also known as NEMO, is a critical regulatory subunit of the IKK complex, which serves as the master switch for the NF-kappa-B signaling pathway [UniProt: Q9Y6K9]. This protein acts as a scaffold, integrating signals from various cell surface receptors, such as TNF receptors and Toll-like receptors, to activate the catalytic IKK alpha and beta subunits [NCBI Gene: 8517]. The IKBKG genomic DNA locus is located on the X chromosome, and mutations within this region are the primary cause of Incontinentia Pigmenti and Anhidrotic Ectodermal Dysplasia with Immunodeficiency [OMIM: 300248]. In many cancers and inflammatory diseases, the NF-kappa-B pathway is constitutively active, making IKBKG an attractive therapeutic target for downregulating pro-survival and pro-inflammatory gene expression [PMID: 24123368]. Current pharmacological strategies focus on disrupting the interaction between IKBKG and the IKK catalytic subunits using small molecules or NEMO-binding domain (NBD) peptides [PMID: 11035755]. While targeting IKBKG offers potent anti-inflammatory effects, it also carries significant risks, such as severe systemic immunodeficiency and potential hepatotoxicity due to the essential role of NF-kappa-B in normal cellular homeostasis and immune function [PMID: 11861203].

Other names

NEMONF-kappa-B essential modulatorFIP-3FIP3FPD7IPIP1IP2IPD2

Inhibition of the IKK complex assembly by disrupting the interaction between the IKBKG regulatory subunit and the IKK alpha/beta catalytic subunits, thereby preventing NF-kappa-B activation [PMID: 24123368].